Browse CD2

Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF05790 Immunoglobulin C2-set domain
PF07686 Immunoglobulin V-set domain
Function

CD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the signaling function.

> Gene Ontology
 
Biological Process GO:0001766 membrane raft polarization
GO:0001773 myeloid dendritic cell activation
GO:0001819 positive regulation of cytokine production
GO:0002274 myeloid leukocyte activation
GO:0002521 leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0007159 leukocyte cell-cell adhesion
GO:0009306 protein secretion
GO:0022407 regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030101 natural killer cell activation
GO:0030217 T cell differentiation
GO:0030885 regulation of myeloid dendritic cell activation
GO:0030887 positive regulation of myeloid dendritic cell activation
GO:0031579 membrane raft organization
GO:0031580 membrane raft distribution
GO:0032609 interferon-gamma production
GO:0032637 interleukin-8 production
GO:0032640 tumor necrosis factor production
GO:0032649 regulation of interferon-gamma production
GO:0032677 regulation of interleukin-8 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032729 positive regulation of interferon-gamma production
GO:0032757 positive regulation of interleukin-8 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0034113 heterotypic cell-cell adhesion
GO:0042110 T cell activation
GO:0045580 regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050900 leukocyte migration
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051665 membrane raft localization
GO:0051668 localization within membrane
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0072606 interleukin-8 secretion
GO:0072643 interferon-gamma secretion
GO:1902105 regulation of leukocyte differentiation
GO:1902713 regulation of interferon-gamma secretion
GO:1902715 positive regulation of interferon-gamma secretion
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903532 positive regulation of secretion by cell
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1903706 regulation of hemopoiesis
GO:1904951 positive regulation of establishment of protein localization
GO:2000482 regulation of interleukin-8 secretion
GO:2000484 positive regulation of interleukin-8 secretion
Molecular Function -
Cellular Component GO:0009897 external side of plasma membrane
GO:0009898 cytoplasmic side of plasma membrane
GO:0031225 anchored component of membrane
GO:0046658 anchored component of plasma membrane
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-109582: Hemostasis
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19293260T-cell malignanciesPromote immunityReductions in CD4(+) and CD8(+) cell count numbers in response to therapy were seen in all patients, but in those patients developing EBV-LPD a significantly greater reduction in natural killer (NK) cell number and CD2 expression on T cells was seen. These findings highlight the importance of NK-cell depletion and CD2 expression in addition to T-cell depletion in the etiology of EBV-LPD.
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.010.987
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1590.924
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.10.939
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6410.137
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5280.674
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7880.637
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9130.154
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3490.292
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4330.76
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.0560.218
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5240.571
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0340.88
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD2
NameCD2 molecule
Aliases CD2 antigen (p50), sheep red blood cell receptor; LFA-2; T11; LFA-3 receptor; T-cell surface antigen T11/Leu ......
Chromosomal Location1p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD2.
ID Name Drug Type Targets #Targets
DB00092AlefaceptBiotechC1QA, C1QB, C1QC, C1R, CD2, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......11
DB06371SiplizumabBiotechCD21